Alphabet Inc. Buys Shares of 372,474 Monte Rosa Therapeutics, Inc. $GLUE
Alphabet Inc. has acquired 372,474 shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) in the second quarter, a new position valued at approximately $9 million. This acquisition gives Alphabet a 0.44% stake in the company, which has seen significant institutional ownership with nearly 80% of its stock held by institutional investors. Despite recent weaker-than-expected quarterly results and some analyst target-price cuts, Monte Rosa Therapeutics still holds a consensus "Moderate Buy" rating from analysts with an average price target of $28.50.
Widening Losses And Profitability Swing Might Change The Case For Investing In Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics reported widening net losses of US$43.4 million for Q2 and US$87.9 million for the first half of 2026, a significant swing from prior-year profitability. This shift deepens the investment risk, as the company's valuation depends heavily on the successful advancement of its clinical programs. Investors must weigh the scientific progress against increased cash burn and potential future dilution.
Widening Losses And Profitability Swing Might Change The Case For Investing In Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics (GLUE) reported widening net losses for Q2 and the first half of 2026, marking a significant shift from prior-year profitability. This financial downturn, with a net loss of US$87.9 million for the six-month period, deepens the investment risk, highlighting the company's reliance on its molecular glue degrader platform and the need for successful clinical trial advancements. Investors must now carefully weigh the potential for future dilution against the scientific progress, as the company's valuation and funding needs become central to its investment narrative.
Monte Rosa Therapeutics (GLUE): Vestal Point discloses 4.6M-share, 5.4% ownership
Vestal Point Capital, LP and Ryan Wilder have disclosed a 5.4% beneficial ownership in Monte Rosa Therapeutics, Inc. (GLUE), totaling 4,600,000 shares of common stock. This passive investment is held through a fund and a managed account advised by Vestal Point Capital, with shared voting and dispositive power over these shares. The ownership percentage is based on 84,479,418 outstanding shares as of May 1, 2026.
Monte Rosa Therapeutics (GLUE) holders report sub‑5% stakes in amended 13G
Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen have filed an amended Schedule 13G for Monte Rosa Therapeutics (GLUE), indicating beneficial ownership below five percent of the outstanding common stock. Montanova Capital and Aaron Cowen each report a 4.2% stake, while Averill Master Fund holds 3.8%. All reporting persons disclaim sole voting or dispositive power, attributing shared authority over their respective holdings.
Industry Analysts Just Upgraded Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Revenue Forecasts By 21%
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has received a significant upgrade to its near-term revenue forecasts by analysts, who now project US$54m in revenue for 2026, an 87% improvement from the last 12 months. Although the consensus price target has fallen by 18% to US$28.50 due to ongoing losses, analysts anticipate substantial acceleration in revenue growth, outperforming the wider industry. However, the company also faces warning signs such as major dilution from new stock issuance.
Industry Analysts Just Upgraded Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Revenue Forecasts By 21%
Analysts have significantly upgraded Monte Rosa Therapeutics, Inc.'s revenue forecasts for 2026 by 21%, now expecting US$54m, an 87% increase from the prior year. Despite the increased revenue projections, the consensus price target has fallen by 18% to US$28.50, indicating that ongoing losses are expected to weigh on the stock price. The company is projected to accelerate its revenue growth to 249% annually by 2026, significantly outpacing its historical growth and the wider industry.
Why Monte Rosa Therapeutics (GLUE) Is Back In Focus After Its Latest Update
Monte Rosa Therapeutics (GLUE) is under scrutiny after reporting increased Q2 net losses of US$43.4 million, leading to a 31.34% share price drop in the last month despite a strong 277.57% year-over-year return. The company, an early-stage biotech, currently trades at a high Price-to-Sales (P/S) ratio of 47x, significantly above its estimated fair value and industry averages, suggesting it may be overvalued. Investors are reassessing risks, focusing on revenue traction and pipeline potential, as its high P/S multiple could unwind if sentiment deteriorates.
Analysts Are Upgrading Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) After Its Latest Results
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) recently released its second-quarter results, showing a significant miss on earnings and increased losses, despite revenue growth. Analysts have since upgraded revenue estimates for 2026 while holding loss per share steady, but the consensus price target has fallen by 18% to US$28.50. The company is expected to grow revenue faster than the industry, with forecasts showing an 87% increase in 2026.
Why Monte Rosa Therapeutics (GLUE) Is Back In Focus After Its Latest Update
Monte Rosa Therapeutics (GLUE) is back in focus after reporting a Q2 net loss of US$43.4 million, larger than the previous year. Despite a recent 31.34% drop in share price over the last month, the company's one-year return is up 277.57%. The article highlights the company's high Price-to-Sales ratio of 47x, significantly above industry averages, suggesting strong market expectations despite Monte Rosa Therapeutics being an early-stage, loss-making biotech.
Analysts Are Upgrading Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) After Its Latest Results
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) recently reported Q2 results that fell short of revenue expectations, leading to increased losses. Despite this, analysts have upgraded 2026 revenue estimates while maintaining loss per share forecasts, indicating a brighter outlook for accelerated growth compared to the industry. However, the consensus price target decreased by 18%, suggesting that ongoing losses are expected to impact the stock price.
What Monte Rosa Therapeutics (GLUE)'s Swing From Profit To Deeper Losses Means For Shareholders
Monte Rosa Therapeutics (GLUE) reported a widened net loss of US$43.4 million in Q2 2026, marking a significant shift from profit to deeper losses over six months. This financial performance highlights increased cost intensity, raising concerns about funding requirements and potential dilution risk for shareholders. The company's investment narrative now focuses more on its funding runway and trial execution, with future capital raises becoming more likely to support ongoing research and development.
MONTE ROSA THERAPEUTICS, INC. : WELLS FARGO CUTS TARGET PRICE TO $27 FROM $29
Wells Fargo has reduced its target price for Monte Rosa Therapeutics, Inc. (NASDAQ: MRTX) shares to $27 from $29. This adjustment indicates a revised outlook from the financial institution regarding the company's future stock performance. The report was published by Reuters.
Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results
Monte Rosa Therapeutics (NASDAQ:GLUE) announced earnings results, reporting a loss of $0.43 per share, missing the consensus estimate of $0.38, and revenue of $8.97 million, below expectations of $12.91 million. Despite the miss, analysts maintain a "Moderate Buy" rating with an average price target of $28.50. Shares rose modestly after the announcement but remain volatile, while insider selling and significant institutional ownership were also noted.
The Manufacturers Life Insurance Company Raises Stake in Monte Rosa Therapeutics, Inc. $GLUE
The Manufacturers Life Insurance Company significantly increased its stake in Monte Rosa Therapeutics, Inc. by 55.8% in Q1, now holding over 209,801 shares valued at $3.45 million. Despite this, Monte Rosa Therapeutics reported weaker-than-expected Q1 results, missing both EPS and revenue estimates. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $28.50, though some targets have been recently reduced.
Dimensional Fund Advisors LP Acquires 473,005 Shares of Monte Rosa Therapeutics, Inc. $GLUE
Dimensional Fund Advisors LP increased its stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 83.2% in the first quarter, purchasing an additional 473,005 shares to own a total of 1.04 million shares, valued at $17.125 million. Other institutional investors also adjusted their positions in GLUE, which has nearly 80% institutional ownership. Despite a recent earnings miss, analysts maintain a "Moderate Buy" consensus rating for the company.
Monte Rosa Therapeutics Is Maintained at Overweight by Wells Fargo
Wells Fargo has reiterated its "Overweight" rating on Monte Rosa Therapeutics. This indicates the firm's positive outlook on the company's stock performance.
Wells Fargo & Company Lowers Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target to $27.00
Wells Fargo & Company has lowered its price target for Monte Rosa Therapeutics (NASDAQ:GLUE) to $27.00 from $29.00, while maintaining an "overweight" rating. This adjustment comes despite the company missing quarterly earnings expectations, reporting a $0.43 per-share loss against an anticipated $0.38 loss and lower-than-expected revenue. Despite the target reduction, analysts largely remain positive, with a "Moderate Buy" consensus and an average target price of $30.33.
Monte Rosa Therapeutics: Q2 Earnings Snapshot
Monte Rosa Therapeutics Inc. (GLUE) reported a Q2 loss of $43.4 million, or 43 cents per share, missing analyst expectations of 25 cents per share. The biopharmaceutical company's revenue for the period was $9 million, also falling short of the $25.7 million anticipated by analysts. These results indicate a weaker-than-expected financial performance for the quarter.
Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q2 Collaboration Revenue $9.0M, Vs. FactSet Est of $12.9M
Monte Rosa Therapeutics, Inc. (GLUE) reported its Q2 collaboration revenue, which came in at $9.0 million. This figure was below FactSet's estimate of $12.9 million. The report provides key financial data for the quarter.
Monte Rosa Therapeutics, Inc. Stock 12‑Month Price Target Cut to $30.33, Implies 94% Upside
Monte Rosa Therapeutics, Inc. (GLUE) has seen its average 12-month price target reduced slightly from $30.67 to $30.33 by analysts, with a range between $25 and $37 per share. This updated target suggests a 94% potential upside from its Aug. 5 closing price. The consensus rating from 8 covering analysts remains a "Buy," with no Hold or Sell recommendations.
Monte Rosa Therapeutics (GLUE) Is Down 30.7% After Deepening Q2 Losses And H1 Earnings Reversal
Monte Rosa Therapeutics (GLUE) reported a significant deepening of Q2 2026 losses to US$43.4 million, up from US$12.3 million a year prior, and a reversal to a net loss of US$87.9 million for H1 2026 from a net income. This financial downturn has led to a 30.7% drop in its stock price, highlighting investor concerns about cash burn, dilution risk, and the company's valuation despite its molecular glue degrader platform. The article suggests the market is now more focused on clinical trial execution and the realism of revenue expectations.
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
Monte Rosa Therapeutics announced its second quarter 2026 financial results and provided several business updates. Key highlights include the completion of enrollment for the GFORCE-1 study of MRT-8102, expected initiation of multiple Phase 2 studies for MRT-8102, activation of a Phase 2 study for MRT-2359, and the activation of a Phase 2a/b clinical trial for MRT-6160 by Novartis. The company reported a strong balance sheet with $626.0 million in cash, cash equivalents, restricted cash, and marketable securities, projected to support operations into 2029.
Monte Rosa Therapeutics (NASDAQ: GLUE) posts 2026 net loss on revenue drop
Monte Rosa Therapeutics reported a significant net loss and a sharp drop in collaboration revenue for Q2 2026 and the first half of 2026. This decline was primarily due to the full recognition of a large Novartis upfront payment in 2025. Despite increased R&D spending to advance its pipeline, the company maintains a cash runway into 2029 due to substantial cash, cash equivalents, and marketable securities.
Press Release: Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
Monte Rosa Therapeutics has announced its financial results for the second quarter of 2026, along with key business updates. The company is providing an overview of its financial performance and strategic advancements during this period.
Monte Rosa Therapeutics earnings missed by $0.05, revenue fell short of estimates
Monte Rosa Therapeutics (NASDAQ: GLUE) reported second-quarter earnings per share of $-0.43, missing analyst estimates by $0.05. The company's revenue of $8.97 million also fell short of the consensus estimate of $12.91 million. Despite the recent earnings miss, the stock has shown significant growth, up 273.05% in the last 12 months, though it's down 19.49% in the last 3 months.
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) reported a Q2 loss of $0.43 per share, missing the Zacks Consensus Estimate of a $0.25 loss, and significantly missed revenue estimates with $8.97 million against a $23.19 million year-ago figure. The company's shares have underperformed the S&P 500 year-to-date, and it currently holds a Zacks Rank #3 (Hold). The article also notes that Fate Therapeutics (FATE), another company in the same industry, is expected to report its Q2 results soon.
Zacks Research Upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to "Hold"
Zacks Research has upgraded Monte Rosa Therapeutics (NASDAQ:GLUE) from a "strong sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with a $30.67 price target. The company recently reported a larger-than-expected quarterly loss of $0.43 per share and revenue below estimates. Insiders have sold approximately $1.77 million worth of shares, while institutional investors and hedge funds hold nearly 80% of the stock.
Monte Rosa Therapeutics reports Q2 2026 net loss $43.4M, cash position $626.0M supporting operations into 2029
Monte Rosa Therapeutics reported a net loss of $43.4 million for Q2 2026, with collaboration revenue reaching $9.0 million. The company's cash position of $626.0 million as of June 30, 2026, is expected to fund operations into 2029. Key business highlights include progress on the MRT-8102 Phase 1 study, plans for multiple Phase 2 studies, and advancements in oncology preclinical programs.
Renaissance Technologies LLC Makes New Investment in Monte Rosa Therapeutics, Inc. $GLUE
Renaissance Technologies LLC has made a new investment in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), purchasing 379,100 shares valued at approximately $6.2 million. This move comes despite the company reporting weaker-than-expected quarterly results and recent insider stock sales. Analysts currently maintain a "Moderate Buy" consensus rating for Monte Rosa Therapeutics, with an average price target of $30.67.
Janus Henderson Group PLC Invests $11.29 Million in Monte Rosa Therapeutics, Inc. $GLUE
Janus Henderson Group PLC has acquired a new stake of 685,926 shares, valued at $11.29 million, in Monte Rosa Therapeutics, Inc. This investment gives Janus Henderson a 0.81% ownership in the company, where institutional investors collectively hold nearly 80%. Despite recent mixed financial results and insider selling, analysts maintain a "Moderate Buy" consensus rating for Monte Rosa Therapeutics.
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 4.1% After Analyst Downgrade
Monte Rosa Therapeutics (NASDAQ:GLUE) shares dropped 4.1% following a Wedbush downgrade, which cut the price target from $37 to $27 while maintaining an outperform rating. The company reported a wider-than-expected quarterly loss of $0.45 per share and significantly missed revenue estimates, posting $4.21 million against a $10.95 million consensus. Insider selling activity also contributed to negative sentiment, with insiders selling over $1.7 million worth of shares in the last three months.
Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target Lowered to $27.00 at Wedbush
Wedbush has lowered its price target for Monte Rosa Therapeutics (NASDAQ:GLUE) to $27.00 from $37.00, while maintaining an "outperform" rating, indicating a potential 63% upside. The adjustment follows Monte Rosa's weaker-than-expected quarterly results, which included a larger-than-anticipated loss per share and lower revenue. Despite the target reduction, analyst sentiment for GLUE remains a "Moderate Buy" with an average target of $30.67.
Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating
Wedbush has revised its price target for Monte Rosa Therapeutics (NASDAQ:GLUE) to $27, down from the previous $37, while reaffirming an Outperform rating. This adjustment reflects a change in the analyst's valuation of the company's prospects.
Arrowstreet Capital Limited Partnership Acquires 340,088 Shares of Monte Rosa Therapeutics, Inc. $GLUE
Arrowstreet Capital Limited Partnership significantly increased its stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 110.5% in the first quarter, now holding 647,739 shares. Despite this strong institutional interest and a "Moderate Buy" consensus from analysts, the company reported weaker-than-expected Q1 earnings, missing revenue and EPS estimates. Shares opened significantly below their 52-week high, and insiders have sold over 81,000 shares in the last ninety days.
Swiss National Bank Invests $1 Million in Monte Rosa Therapeutics, Inc. $GLUE
The Swiss National Bank has acquired a new stake of 61,100 shares, valued at $1.005 million, in Monte Rosa Therapeutics ($GLUE) during the first quarter. This investment is part of broader institutional interest, with institutional investors now owning nearly 80% of the company despite a recent stock decline and missed Q1 earnings estimates. Analysts maintain a "Moderate Buy" rating for Monte Rosa Therapeutics, setting an average price target of $32.33.
Why Monte Rosa Therapeutics (GLUE) Is Down 27.5% After Novo Nordisk’s ZEUS Trial Missed Its Goal
Monte Rosa Therapeutics (GLUE) saw its stock drop 27.5% after Novo Nordisk's ZEUS trial for an anti-inflammatory drug failed to meet its primary goal, increasing scrutiny on inflammation-focused biotechs. This setback highlights potential scientific and regulatory risks for Monte Rosa's own inflammation programs, amplifying an already volatile share price and raising concerns about its investment narrative. Despite the broader market reaction, Monte Rosa's near-term catalysts still center on oncology and autoimmune readouts and partnership progress.
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Gap Down - Should You Sell?
Monte Rosa Therapeutics (NASDAQ:GLUE) experienced a significant share price drop of 29.4% after opening at $15.47, down from its prior close of $22.68, following a missed earnings report. The company reported a quarterly loss worse than expected and revenue significantly below estimates. Despite this, analyst sentiment is a "Moderate Buy" with an average price target of $34.83, though insiders have been selling shares.
Why Monte Rosa Therapeutics (GLUE) Is Down 27.5% After Novo Nordisk’s ZEUS Trial Missed Its Goal
Monte Rosa Therapeutics (GLUE) saw its stock price drop by 27.5% after Novo Nordisk's ZEUS trial for an anti-inflammatory drug failed to meet its primary goal, impacting investor confidence in the broader inflammation-focused drug market. This setback has intensified scrutiny on Monte Rosa's scientific approach and pipeline risk, particularly its inflammation programs, leading to increased market volatility. While Monte Rosa's core near-term catalysts remain in oncology and autoimmune readouts, the market is now more risk-averse regarding its inflammation-related pipeline.
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Consensus Recommendation of "Moderate Buy" by Analysts
Monte Rosa Therapeutics (NASDAQ:GLUE) has received a "Moderate Buy" consensus recommendation from analysts, with seven rating it a buy and two a sell. The average 12-month price target is $34.83, significantly above its $21.52 opening price. Despite this, the company reported a larger-than-expected quarterly loss and lower revenue, and insiders have sold off $1.77 million in shares.
Monte Rosa Therapeutics (GLUE) to Release Earnings on Thursday
Monte Rosa Therapeutics (GLUE) is set to release its Q2 2026 earnings before market open on Thursday, August 6th, with analysts forecasting a loss of $0.3657 per share and revenue of $12.9 million. The company missed expectations in the previous quarter, and its stock GLUE opened at $21.52, between its 52-week low and high. Analysts maintain a "Moderate Buy" consensus with a price target of $34.83, despite insider selling of 81,778 shares over the past 90 days.
GLUE|Monte Rosa Therapeutics Inc|Price:21.600|Chg%:-0.440
Monte Rosa Therapeutics Inc. (GLUE) is a clinical-stage biotechnology company developing novel molecular glue degraders. The article highlights the company's relatively healthy fundamentals, significant growth potential, and fair valuation within the Biotechnology & Medical Research industry. Institutional ownership is high, and analysts have issued "Buy" ratings with a target price of $35.60, indicating an expected upward trend in the medium term despite recent weak stock market performance.
Exome Asset Management LLC Takes $2.95 Million Position in Monte Rosa Therapeutics, Inc. $GLUE
Exome Asset Management LLC has acquired a new stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) worth approximately $2.95 million, making it the 24th largest holding for the firm. Despite Monte Rosa missing recent earnings and revenue expectations, analysts have a "Moderate Buy" consensus with an average price target significantly above its current trading price. Insider transactions show recent sales of GLUE shares by company executives.
Monte Rosa Therapeutics Inc (GLUE) Cash Flow
This article provides a detailed cash flow statement for Monte Rosa Therapeutics Inc (GLUE), presenting quarterly and annual data for operating, investing, and financing activities. It includes year-over-year percentage changes and absolute financial figures. The piece also features a "FAQs" section clarifying what operating, investing, and financing cash flows are, their significance, and specific figures for GLUE's recent performance.
Monte Rosa Therapeutics, Inc. Revenue Breakdown – BOATS:GLUE
Monte Rosa Therapeutics, Inc. (GLUE) generated $123.70 million USD in revenue last year, primarily from its Novel Small Molecule Precision Medicines segment, which accounted for $123.67 million USD. The majority of the revenue, $111.30 million USD, originated from Switzerland. This represents an increase from the previous year's total revenue of $75.62 million USD.
Monte Rosa Therapeutics Inc (GLUE) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Monte Rosa Therapeutics Inc (GLUE), listing major individual shareholders and their proportions, as well as the types of shareholder entities. It also provides institutional shareholding data over several quarters and lists related ETFs that hold GLUE shares. The information aims to offer insights into the ownership distribution of the company.
Monte Rosa Therapeutics Market Sentiment
This article analyzes Monte Rosa Therapeutics (GLUE) market sentiment through analyst consensus, short interest, options flow, and insider activity. The consensus is "Overweight" with a price target of $24, but rising short interest and net insider selling indicate some bearish sentiment. The article also lists recent analyst actions with price target changes and ratings.
Price to sales forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE
This article provides the "Price to sales forward" financial metric for Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) as part of its financial data on TradingView. The content is concise, focusing solely on this specific valuation ratio for the company.
Price to sales forward of Monte Rosa Therapeutics, Inc. – BOATS:GLUE
This article provides the "Price to sales forward" financial metric for Monte Rosa Therapeutics, Inc. (GLUE) on the Blue Ocean Alternative Trade System (BOATS) platform. The content primarily consists of navigation and boilerplate text from the TradingView platform, indicating the specific financial data point being presented for the company.
Allspring Global Investments Holdings LLC Buys 365,272 Shares of Monte Rosa Therapeutics, Inc. $GLUE
Allspring Global Investments Holdings LLC significantly increased its stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 1,355.1% in the first quarter, now owning 392,227 shares valued at $6.45 million. Other institutional investors like Price T Rowe and Vanguard also boosted their holdings, with institutional ownership for GLUE remaining high at 79.96%. The company has a "Moderate Buy" consensus rating from analysts with an average price target of $33.33, despite recent quarterly losses and lower-than-expected revenue.
